Aiweigrin Pharmaceutical Technology

Aiweigrin Pharmaceutical Technology is a China-based biotechnology company focused on the discovery and development of targeted protein degradation (TPD) therapeutics. Utilizing its proprietary PROTAC and molecular glue platforms, the company addresses challenging targets in oncology and immunology that are often inaccessible via traditional small molecule inhibitors. Aiweigrin operates out of the Suzhou BioBay industrial park, providing both internal pipeline development and contract research services to global partners. Their lead programs focus on degrading key drivers of hematologic malignancies and solid tumors, such as BTK and hormone receptors. The company is dedicated to overcoming drug resistance in cancer through innovative medicinal chemistry and degradation biology.